A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients

Inclusion Criteria: 1. Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label 2. Patients who are willing to provide written informed consent prior to study enrollment Exclusion Criteria: 1. Patients under 12 years old 2. Patients with contraindication according to locally approved label of Jakavi® 3. Patients who receive or are going to receive any investigational medicine during the observation period.